Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-30

Surmodics (SRDX)

CEO Gary Maharaj was paid $3,665,496 in fiscal year 2024, ↑ up 3.9% from fiscal year 2023, the 33rd percentile of its disclosed peer group (SEC filing 0000950170-24-138240 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,665,496 ↑
Gary Maharaj total, FY2024
33rd
CEO pay percentile vs peers
—
CEO-to-median pay ratio
87.66%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Gary Maharaj (President and Chief Executive Officer), FY2024 total compensation $3,665,496 (base salary $647,481) [exec_comp, SEC accession 0000950170-24-138240, filed 2024-12-19]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Gary Maharaj$647,481$0$940,000$1,410,000$654,215$0$13,800$3,665,496
President and Chief Executive Officer
Teryl Sides446,8440312,000468,000282,182012,3441,521,370
Senior Vice President and President, Vascular Interventions
Timothy Arens386,5880280,000420,000244,130013,7931,344,511
Senior Vice President of Finance and Information Technology and Chief Financial Officer
Gordon Weber361,9870220,000330,000228,59506,1131,146,695
Senior Vice President of Legal, General Counsel and Secretary
Charles Olson361,9870212,000318,000233,30108,8271,134,115
Senior Vice President and President, Medical Device Coatings

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Gary Maharaj$3,665,496$3,527,263$3,095,627↑ +138,233
Teryl Sides1,521,3701,494,3751,113,022↑ +26,995
Timothy Arens1,344,5111,295,2991,045,826↑ +49,212
Gordon Weber1,146,6951,102,8401,019,595↑ +43,855
Charles Olson1,134,1151,118,4701,023,119↑ +15,645

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Surmodics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SRDX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against SRDX
10 companies name SRDX as a compensation peer

Each company listed discloses SRDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SRDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Charles OlsonSVP$1,134,115
Gary MaharajCEO$3,665,496
Teryl SidesSVP$1,521,370
Timothy ArensCFO$1,344,511
Gordon WeberGeneral Counsel$1,146,695
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
David R. Dantzker, M.DIndependent Director$185,000
José H. BedoyaIndependent Director$176,500
Lisa W. HeineIndependent Director$181,500
Ronald B. KalichFormer director (through FY2024)$173,250
Susan E. KnightChair of the Board$234,000
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Susan E. KnightDirector2025-01-24A7,358$27$200,873CommonForm 4 ↗
Susan E. KnightDirector2025-01-24D7,35800Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-01-24D5,26638200,898CommonForm 4 ↗
David DantzkerDirector2025-02-13D5,27500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-02-13D4,21634144,019CommonForm 4 ↗
David DantzkerDirector2025-02-13A5,27527144,008CommonForm 4 ↗
José H. BedoyaDirector2025-02-14D5,27500Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-02-14D4,22434144,038CommonForm 4 ↗
José H. BedoyaDirector2025-02-14A5,27527144,008CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18A2,6402772,072CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18D2,64000Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18D2,1153472,100CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D20,10100Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D29,58200Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D40,183——CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D28,86400Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D61,631——CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,63400Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D12,29200Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D21,040——CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D8,155——CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D10,65300Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D51,478——CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D13,978——CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D20,85900Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D25,01600Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,19600Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D2,61500Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D11,53800Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D800——CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D13,57900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D45,07300Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D192,056——CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D89,12700Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D84,66900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D73,34900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D74,51500Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D62,67400Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D20,10100Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D12,29200Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D26,54800Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D10,65300Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D67,299——CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D30,008——CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D4,15500Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D5,04000Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D4,54800Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D37,240——CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D8,35600Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D5,46300Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D34,703——CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D3,16000Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D4,81000Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D4,58400Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2025-11-19—3,602——1 insider, 2 accrual rows
Charles OlsonSVP, Medical Device Coatings2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 91 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Susan E. KnightDirector2025-01-24A7,358$27$200,873CommonForm 4 ↗
Susan E. KnightDirector2025-01-24D7,35800Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-01-24D5,26638200,898CommonForm 4 ↗
David DantzkerDirector2025-02-13D5,27500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-02-13D4,21634144,019CommonForm 4 ↗
David DantzkerDirector2025-02-13A5,27527144,008CommonForm 4 ↗
José H. BedoyaDirector2025-02-14D5,27500Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-02-14D4,22434144,038CommonForm 4 ↗
José H. BedoyaDirector2025-02-14A5,27527144,008CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18A2,6402772,072CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18D2,64000Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-02-18D2,1153472,100CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D20,10100Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D29,58200Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D40,183——CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D28,86400Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D61,631——CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,63400Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D12,29200Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D21,040——CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D8,155——CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D10,65300Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D51,478——CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D13,978——CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D20,85900Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D25,01600Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D3,19600Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D2,61500Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Gordon WeberSr. VP of Legal, GC and Sec.2025-11-19D11,53800Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D800——CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D13,57900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D45,07300Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D192,056——CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D89,12700Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D84,66900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D73,34900Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D74,51500Derivative, Class A CommonForm 4 ↗
Gary R. MaharajDirector2025-11-19D62,67400Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D20,10100Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D19,24300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Joseph J. StichSVP of HR, President IVD2025-11-19D12,29200Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D26,54800Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D10,65300Derivative, Class A CommonForm 4 ↗
Timothy ArensChief Financial Officer2025-11-19D67,299——CommonForm 4 ↗
José H. BedoyaDirector2025-11-19D30,008——CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D4,15500Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D5,04000Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D4,54800Derivative, Class A CommonForm 4 ↗
Susan E. KnightDirector2025-11-19D37,240——CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D4,67400Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
Lisa W. HeineDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D3,85300Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D3,55500Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D2,96400Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D4,21800Derivative, Class A CommonForm 4 ↗
David DantzkerDirector2025-11-19D2,60500Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D15,66800Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D8,35600Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D5,46300Derivative, Class A CommonForm 4 ↗
Teryl SidesSVP, Vascular Interventions2025-11-19D34,703——CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D3,16000Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D4,81000Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D4,58400Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D1,86200Derivative, Class A CommonForm 4 ↗
John D. MandersVP Finance, Corp. Controller2025-11-19D1,74000Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D18,33700Derivative, Class A CommonForm 4 ↗
Charles OlsonSVP, Medical Device Coatings2025-11-19D17,88300Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Timothy ArensRSU2023-12-04——8,323—$280,000
Gordon WeberRSU2023-12-04——6,539—220,000
Charles OlsonRSU2023-12-04——6,302—212,000
Gary MaharajRSU2023-12-04——27,942—940,000
Teryl SidesRSU2023-12-04——9,274—312,000
Gary MaharajOPTION2023-12-04——89,127—1,410,000
Charles OlsonOPTION2023-12-04——20,101—318,000
Teryl SidesOPTION2023-12-04——29,582—468,000
Timothy ArensOPTION2023-12-04——26,548—420,000
Gordon WeberOPTION2023-12-04——20,859—330,000
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Timothy Arens$280,000$0$420,0000.0%
Gordon Weber220,0000330,0000.0%
Charles Olson212,0000318,0000.0%
Gary Maharaj940,00001,410,0000.0%
Teryl Sides312,0000468,0000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Gary MaharajRSU2,977,230—$115,457,005
Gary MaharajRSU1,374,065—53,286,253
Teryl SidesRSU1,335,396—51,786,585
Charles OlsonRSU39,915—2,003,754
Timothy ArensRSU1,155,320—44,803,318
Charles OlsonRSU1,081,800—41,952,145
Gordon WeberRSU1,081,800—41,952,135
Teryl SidesRSU450,468—17,469,125
Timothy ArensRSU402,243—15,598,986
Gordon WeberRSU319,247—12,380,378
Charles OlsonRSU312,152—12,105,238
Teryl SidesRSU42,502—2,605,384
Timothy ArensRSU44,275—2,306,229
Gary MaharajRSU40,093—1,554,807
Gary MaharajRSU27,942—1,083,591
Gordon WeberRSU18,123—702,809
Gary MaharajRSU16,237—629,671
Teryl SidesRSU9,274—359,646
Timothy ArensRSU8,323—322,766
Gordon WeberRSU6,539—253,582
Charles OlsonRSU6,302—244,392
Gary MaharajRSU6,070—235,395
Teryl SidesRSU5,535—214,647
Timothy ArensRSU4,797—186,028
Charles OlsonRSU3,690—143,098
Gordon WeberRSU3,690—143,098
Timothy ArensRSU1,517—58,829
Charles OlsonRSU1,517—58,829
Teryl SidesRSU1,517—58,829
Gordon WeberRSU1,517—58,829
Gary MaharajOption18,62937.44—
Gary MaharajOption36,67443.93—
Gary MaharajOption63,50236.13—
Gary MaharajOption89,12733.64—
Timothy ArensOption4,47137.44—
Timothy ArensOption9,16843.93—
Teryl SidesOption29,58233.64—
Timothy ArensOption18,76236.13—
Timothy ArensOption26,54833.64—
Charles OlsonOption4,47137.44—
Charles OlsonOption9,16843.93—
Charles OlsonOption14,43236.13—
Charles OlsonOption20,10133.64—
Teryl SidesOption4,47137.44—
Teryl SidesOption9,16843.93—
Teryl SidesOption21,64836.13—
Gordon WeberOption4,47137.44—
Gordon WeberOption9,16843.93—
Gordon WeberOption14,43236.13—
Gordon WeberOption20,85933.64—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is performance-based and focuses on aligning the financial interests of our executive officers with those of our shareholders by placing a substantial portion of total compensation 'at risk' while providing overall compensation opportunities that are comparable to market levels.

CEO STI target (% of salary)80%
CEO LTI target (% of salary)—
Independent consultantPay Governance LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-02-067,415,3391,043,557132,99387.66%Passed
20242024-02-089,588,433650,24510,35393.65%Passed
20232023-02-0911,173,618669,81816,65594.34%Passed
20222022-02-1011,084,992591,65816,82694.93%Passed
20212021-02-1111,234,762274,98342,47897.61%Passed
20202020-02-1310,662,542296,40082,20897.3%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-02-0687.66%a
20242024-02-0893.65%b
20232023-02-0994.34%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Susan E. KnightIndependent · Board Chair · Audit (Chair)$110,000$62,000$62,000——$234,000
David R. Dantzker, M.DIndependent · Organization and Compensation (Chair) · Corporate Governance and Nominating · Audit70,00057,50057,500——185,000
Lisa W. HeineIndependent · Organization and Compensation · Corporate Governance and Nominating · Audit66,50057,50057,500——181,500
José H. BedoyaIndependent · Corporate Governance and Nominating (Chair) · Organization and Compensation61,50057,50057,500——176,500
Ronald B. KalichIndependent · Departed during FY58,25057,50057,500——173,250
Gary R. MaharajEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$115,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 15,000 / 10,000
Stock ownership guideline$5
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$366,250
Equity awards (grant-date value)$292,000
All other compensation$0
Total cost of the board$658,250

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Surmodics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Surmodics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1AtriCure, Inc.2025Michael Carrel$828,439$7,203,478$0$1,171,703$9,217,620
2AxoGen, Inc.2025Michael Dale775,8657,342,8950906,1339,047,454
3SI-BONE, Inc.2025Laura Francis685,0006,038,7100729,5257,453,235
4Cutera, Inc.2023Taylor Harris271,0232,747,6824,250,00807,279,813
5Artivion Inc.2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
6OraSure Technologies, Inc.2025Carrie Eglinton Manner721,0003,394,1880173,0404,292,228
7Cerus Corporation2025William Greenman793,7502,242,5850756,0003,794,657
8LeMaitre Vascular, Inc.2025George LeMaitre806,3471,050,0001,050,000680,0153,780,990
9Surmodics2024Gary Maharaj647,481940,0001,410,000654,2153,665,496
10Tactile Systems Technology, Inc.2025Sheri Dodd675,0002,019,9780737,4383,466,916
11NeuroPace, Inc.2025Joel Becker567,567587,340701,850551,8102,408,566
12Anika Therapeutics Inc.2025Stephen Griffin500,0001,215,222002,033,370
13Atrion Corp.2023David Battat718,07700180,000924,464
—Pulmonx Corporation——————not in coverage universe
—Conformis, Inc.——————not in coverage universe
—Xtant Medical Holdings, Inc.——————not in coverage universe
—Cardiovascular Systems Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Surmodics126.3%Option 60 · Restricted Shares 40not disclosedPay Governance LLC
Anika Therapeutics Inc.100%PSU 67 · RSU 33NoWillis Towers Watson
Artivion Inc.118.7%PSU 50 · RSU 50NoWillis Towers Watson
AtriCure, Inc.141%PSU 70 · RSU 30NoKorn Ferry
Atrion Corp.25%RSU 100not disclosedFW Cook
AxoGen, Inc.116.79%PSU 50 · RSU 50NoAon
Cardiovascular Systems Inc.not disclosednot disclosednot disclosednot disclosed
Cerus Corporation126%not disclosedNoAlpine
Conformis, Inc.not disclosednot disclosednot disclosednot disclosed
Cutera, Inc.not disclosednot disclosedNoCompensia
LeMaitre Vascular, Inc.not disclosedOption 50 · RSU 25 · PSU 25Nonot disclosed
NeuroPace, Inc.not disclosednot disclosednot disclosedAlpine, Inc.
OraSure Technologies, Inc.24.0%RSU 50 · PSU 50Yes — Relative TSR performance vs peer groupPay Governance
Pulmonx Corporationnot disclosednot disclosednot disclosednot disclosed
SI-BONE, Inc.106.5%RSU 50 · PSU 50Yes — Relative TSRCompensia, Inc.
Tactile Systems Technology, Inc.115%PSU 50 · RSU 50NoAon Consulting, Inc.
Xtant Medical Holdings, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Surmodics in fiscal 2024?
As disclosed, Gary Maharaj (President and Chief Executive Officer) was the highest-paid executive at Surmodics in fiscal 2024, with total compensation of $3,665,496.
How does Surmodics's chief executive pay compare to its disclosed peer group?
As disclosed, Gary Maharaj's total compensation ranked at the 33rd percentile of Surmodics's disclosed peer group.
How did shareholders vote on Surmodics's executive compensation?
As disclosed, 87.66% of shareholders supported Surmodics's executive compensation in the latest say-on-pay vote.
How much does Surmodics spend in total on board compensation for fiscal 2024?
As disclosed, Surmodics reported total board compensation of $658,250 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Gary MaharajDEF 14A2024-12-190000950170-24-138240Section “Summary Compensation Table” · page 37. As printed: 3,665,496. Filing ↗machine: r3 · c25 · span 1568790–1568799
2Section 01, Teryl SidesDEF 14A2024-12-190000950170-24-138240Section “Summary Compensation Table” · page 37. As printed: 1,521,370. Filing ↗machine: r12 · c25 · span 1649599–1649608
3Section 01, Timothy ArensDEF 14A2024-12-190000950170-24-138240Section “Summary Compensation Table” · page 37. As printed: 1,344,511. Filing ↗machine: r6 · c25 · span 1595678–1595687
4Section 01, Gordon WeberDEF 14A2024-12-190000950170-24-138240Section “Summary Compensation Table” · page 37. As printed: 1,146,695. Filing ↗machine: r15 · c25 · span 1676541–1676550
5Section 01, Charles OlsonDEF 14A2024-12-190000950170-24-138240Section “Summary Compensation Table” · page 37. As printed: 1,134,115. Filing ↗machine: r9 · c25 · span 1622649–1622658
6Section 03, Timothy Arens RSUDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r8 · c17 · span 1786179–1786184
7Section 03, Gordon Weber RSUDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r17 · c17 · span 1870200–1870205
8Section 03, Charles Olson RSUDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r11 · c17 · span 1814186–1814191
9Section 03, Gary Maharaj RSUDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r5 · c17 · span 1758186–1758192
10Section 03, Teryl Sides RSUDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r14 · c17 · span 1842194–1842199
11Section 03, Gary Maharaj OPTIONDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r6 · c20 · span 1768507–1768513
12Section 03, Charles Olson OPTIONDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r12 · c20 · span 1824523–1824529
13Section 03, Teryl Sides OPTIONDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r15 · c20 · span 1852531–1852537
14Section 03, Timothy Arens OPTIONDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r9 · c20 · span 1796516–1796522
15Section 03, Gordon Weber OPTIONDEF 14A2024-12-190000950170-24-138240Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. Filing ↗machine: t112 · r18 · c20 · span 1880537–1880543
16Section 08, Susan E. KnightDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 234,000. Filing ↗machine: span 556376–556621
17Section 08, David R. Dantzker, M.DDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 185,000. Filing ↗machine: span 567618–567863
18Section 08, Lisa W. HeineDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 181,500. Filing ↗machine: span 573231–573476
19Section 08, José H. BedoyaDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 176,500. Filing ↗machine: span 561995–562240
20Section 08, Ronald B. KalichDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 173,250. Filing ↗machine: span 579007–579252
21Section 08, Gary R. MaharajDEF 14A2024-12-190000950170-24-138240Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Susan E. Knight 2025-01-24Form 42025-01-280000950170-25-009976Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Susan E. Knight 2025-01-24Form 42025-01-280000950170-25-009976Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Susan E. Knight 2025-01-24Form 42025-01-280000950170-25-009976Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, David Dantzker 2025-02-13Form 42025-02-180000950170-25-022487Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, David Dantzker 2025-02-13Form 42025-02-180000950170-25-022487Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, David Dantzker 2025-02-13Form 42025-02-180000950170-25-022487Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, José H. Bedoya 2025-02-14Form 42025-02-180000950170-25-022479Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, José H. Bedoya 2025-02-14Form 42025-02-180000950170-25-022479Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, José H. Bedoya 2025-02-14Form 42025-02-180000950170-25-022479Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Lisa W. Heine 2025-02-18Form 42025-02-200000950170-25-024156Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Lisa W. Heine 2025-02-18Form 42025-02-200000950170-25-024156Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Lisa W. Heine 2025-02-18Form 42025-02-200000950170-25-024156Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Gordon Weber 2025-11-19Form 42025-11-190001193125-25-288450Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Gary R. Maharaj 2025-11-19Form 42025-11-190001193125-25-288424Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Joseph J. Stich 2025-11-19Form 42025-11-190001193125-25-288427Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Timothy Arens 2025-11-19Form 42025-11-190001193125-25-288432Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, José H. Bedoya 2025-11-19Form 42025-11-190001193125-25-288436Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Susan E. Knight 2025-11-19Form 42025-11-190001193125-25-288439Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Lisa W. Heine 2025-11-19Form 42025-11-190001193125-25-288441Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, David Dantzker 2025-11-19Form 42025-11-190001193125-25-288443Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Teryl Sides 2025-11-19Form 42025-11-190001193125-25-288446Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, John D. Manders 2025-11-19Form 42025-11-190001193125-25-288452Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Charles Olson 2025-11-19Form 42025-11-190001193125-25-288455Insider equity transaction reported since the proxy statement. Filing ↗
113Section 06, 2025 voteForm 8-K2025-02-100000950170-25-016772Item 5.07 · say-on-pay result. As reported: 87.66% (votes for as printed: 7,415,339). Filing ↗
114Section 06, 2024 voteForm 8-K2024-02-120000950170-24-013859Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 9,588,433). Filing ↗
115Section 06, 2023 voteForm 8-K2023-02-130001157523-23-000265Item 5.07 · say-on-pay result. As reported: 94.34% (votes for as printed: 11,173,618). Filing ↗
116Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
117Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
118Section 09b board cost (computed)Computed——Cash 366,250 + equity 292,000 + all other 0 = 658,250, summed across the director compensation table rows.machine: formula: Σ = 658,250
119AtriCure, Inc., Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
120AxoGen, Inc., Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
121SI-BONE, Inc., Section 10b CEO totalDEF 14A2026-04-210001459839-26-000049CEO total compensation as printed in SI-BONE, Inc.'s own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978
122Cutera, Inc., Section 10b CEO totalDEF 14A2024-06-170001628280-24-028528CEO total compensation as printed in Cutera, Inc.'s own proxy. As printed: 7,279,813. Filing ↗machine: r4 · c46 · span 1221355–1221364
123Artivion Inc., Section 10b CEO totalDEF 14A2026-04-010001999371-26-007510CEO total compensation as printed in Artivion Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882
124OraSure Technologies, Inc., Section 10b CEO totalDEF 14A2026-04-300001116463-26-000032CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385
125Cerus Corporation, Section 10b CEO totalDEF 14A2026-04-220001020214-26-000011CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. Filing ↗machine: span 1301658–1301667
126LeMaitre Vascular, Inc., Section 10b CEO totalDEF 14A2026-04-140001193125-26-153877CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: r3 · c18 · span 564038–564047
127Surmodics (subject), Section 10b CEO totalDEF 14A2024-12-190000950170-24-138240CEO total compensation as printed in Surmodics's own proxy. As printed: 3,665,496. Filing ↗machine: r3 · c25 · span 1568790–1568799
128Tactile Systems Technology, Inc., Section 10b CEO totalDEF 14A2026-03-250001104659-26-034206CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806
129NeuroPace, Inc., Section 10b CEO totalDEF 14A2026-04-210001140361-26-015894CEO total compensation as printed in NeuroPace, Inc.'s own proxy. As printed: 2,408,566. Filing ↗machine: r2 · c21 · span 339764–339773
130Anika Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-280001140361-26-017488CEO total compensation as printed in Anika Therapeutics Inc.'s own proxy. As printed: 2,033,370. Filing ↗machine: r5 · c22 · span 1052517–1052526
131Atrion Corp., Section 10b CEO totalDEF 14A2024-04-090001104659-24-044922CEO total compensation as printed in Atrion Corp.'s own proxy. As printed: 924,464. Filing ↗machine: r1 · c47 · span 467910–467917
132Section 10a, Cerus Corporation reciprocityDEF 14A—0001020214-26-000011Cerus Corporation's most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
133Section 10a, AxoGen, Inc. reciprocityDEF 14A—0000805928-26-000057AxoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
134Section 10a, Anika Therapeutics Inc. reciprocityDEF 14A—0001140361-26-017488Anika Therapeutics Inc. names Surmodics in its own disclosed peer group (read from its most recent proxy). Filing ↗
135Section 10a, OraSure Technologies, Inc. reciprocityDEF 14A—0001116463-26-000032OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
136Section 10a, AtriCure, Inc. reciprocityDEF 14A—0001323885-26-000010AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
137Section 10a, Cutera, Inc. reciprocityDEF 14A—0001628280-24-028528Cutera, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
138Section 10a, SI-BONE, Inc. reciprocityDEF 14A—0001459839-26-000049SI-BONE, Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
139Section 10a, Artivion Inc. reciprocityDEF 14A—0001999371-26-007510Artivion Inc.'s most recent proxy was read; its disclosed peer group does not include Surmodics. Filing ↗
140Section 10a, LeMaitre Vascular, Inc. reciprocityDEF 14A—0001437749-23-010217LeMaitre Vascular, Inc. names Surmodics in its own disclosed peer group (read from its most recent proxy). Filing ↗
141Section 10a, Tactile Systems Technology, Inc. reciprocityDEF 14A—0001104659-26-034206Tactile Systems Technology, Inc. names Surmodics in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.